New publication reaffirms high performance of ROCA® in detecting ovarian cancer
New publication shows that the ROCA Test can detect twice as many ovarian cancers than single assessment of CA125 and detects the most aggressive forms of cancer.Read More
Outstanding Results from Major Ovarian Cancer Screening Trial Shows the High Performance of ROCA®, Paving the Way for its Launch by Abcodia
ROCA® continues to be validated in a major ovarian cancer screening study (UKCTOCS) and a new publication reports that it detected twice as many malignancies than the traditional single assessment of CA125 level.Read More
International Clinical Trials: how can you develop biomarker-based tests efficiently without extra trials that add to development time and cost?
Biomarker-based tests are becoming a necessity for much therapeutic research, but they add unwelcome time and cost. In the drive for efficiency, drug developers should focus on appropriate biomarker selection and using biobanks for pre-trial validation work.Read More
Three New Companies Join Cancer Research UK-Abcodia Collaboration to Identify Blood Markers for Early Cancer Detection
THREE NEW BIOMARKER COMPANIES have been selected to work with the Early Diagnosis Consortium, a collaboration between Cancer Research UK, its commercial arm, Cancer Research Technology, and Abcodia, a specialist company engaged in the validation of biomarkers for the early detection and screening of cancer.Read More